Rudolph Virchow, in 1854, introduced and popularized the term amyloid to denote a macroscopic tissue abnormality that exhibited a positive iodine staining reaction. Subsequent light microscopic studies with polarizing optics demonstrated the inherent birefringence of amyloid deposits, a property that increased intensely after staining with Congo red dye. In 1959, electron microscopic examination of ultrathin sections of amyloidotic tissues revealed the presence of fibrils, indeterminate in length and, invariably, 80 to 100 Å in width. Using the criteria of Congophilia and fibrillar morphology, 20 or more biochemically distinct forms of amyloid have been identified throughout the animal kingdom; each is specifically associated with a unique clinical syndrome. Fibrils, also 80 to 100 Å in width, have been isolated from tissue homogenates using differential sedimentation or solubility. X-ray diffraction analysis revealed the fibrils to be ordered in the beta pleated sheet conformation, with the direction of the polypeptide backbone perpendicular to the fibril axis (cross beta structure). Because of the similar dimensions and tinctorial properties of the fibrils extracted from amyloid-laden tissues and amyloid fibrils in tissue sections, they have been assumed to be identical. However, the spatial relationship of proteoglycans and amyloid P component (AP), common to all forms of amyloid, to the putative protein only fibrils in tissues, has been unclear. Recently, it has been suggested that, in situ, amyloid fibrils are composed of proteoglycans and AP as well as amyloid proteins and thus resemble connective tissue microfibrils. Chemical and physical definition of the fibrils in tissues will be needed to relate the in vitro properties of amyloid protein fibrils to the pathogenesis of amyloid fibril formation in vivo. © 2000 Academic Press Key Words: amyloid fibril; amyloid protein; amyloidosis; electron microscopy; history
The term amyloid was introduced in 1854 by the German physician scientist Rudolph Virchow (reviewed by Cohen, 1986) . Utilizing the best scientific methodology and medical knowledge of the time, Virchow used iodine to stain cerebral corpora amylacea that had an abnormal macroscopic appearance. The macroscopic appearance of the brain tissue was similar to previous descriptions of other tissues, perhaps as early as 1639, as lardaceous liver, waxy liver, and spongy and "white stone" containing spleens (Fig. 1) . When Virchow discovered that the corpora amylacea stained pale blue on treatment with iodine, and violet upon the subsequent addition of sulfuric acid, he concluded that the substance underlying the evident macroscopic abnormality was cellulose and gave it the name amyloid, derived from the Latin amylum and the Greek amylon (reviewed by Cohen, 1986) . At the time, the distinction between starch and cellulose, as related to the separation of the plant and animal kingdoms, was unclear. From subsequent literature (reviewed by Cohen, 1986) , Virchow evidently considered the amyloid substance to be starch, although there was confusion as to whether amyloid denotes cellulose or starch. When, in 1859, Friedreich and Kekule (reviewed by Cohen, 1986 ) demonstrated both the presence of protein in a "mass" of amyloid and the apparent absence of carbohydrate based on the high nitrogen content, attention was shifted to the study of amyloid first as a protein and later as a class of proteins, with a propensity to undergo changes in conformation that result in fibril formation.
During the 19th and early 20th centuries, investigations on the nature of amyloid evolved from the macroscopic observations of Virchow and contempo-FIG. 1. Amyloid deposits at low magnification; (a) attributed to Frerichs, 1862; (b) polarization microscopy of Congo red-stained nerve biopsy from patient with ATTR, V30M; original magnification, ϫ6.3; (c) polarization microscopy of Congo red-stained heart tissue, original magnification, ϫ16. 89 raries ( Fig. 1) to classifications of clinical symptoms (Table I) . The term amyloid has been used to describe specific macroscopic abnormalities on autopsy of body organs and tissues of patients afflicted with a variety of clinical syndromes that were first classified as idiopathic (primary) or myeloma-associated, acquired (secondary), local, hereditary, endocrine associated, and amyloid associated with aging (Table I) . While introducing the term amyloid is not one of Virchow's widely known achievements, this distinguished scientist and advocate for public health's use of a unifying nomenclature has led to a fascinating field of biomedical research.
MICROSCOPIC STUDIES OF AMYLOID STRUCTURE
Our understanding of amyloid structure has advanced with the available technology. Thus, investigators began to utilize, as they became available, light microscopy and histopathologic dyes such as thioflavin and Congo red. Initially, they concluded that amyloid of a variety of sources was structurally amorphous. However, subsequent polarization light microscopic studies (Divry and Florkin, 1927) demonstrated that unstained and Congo red-stained accumulations of amyloid in a variety of tissues exhibited positive birefringence with respect to the long axis of the deposits. Thus, Congo red staining imparts a marked anisotropy to the inherent birefringence exhibited by amyloid fibrils in situ (Missmahl and Hartwig, 1953) . Congophilia with apple green birefringence was the first criterion of amyloid to be adopted (Fig. 2) .
The possibility of an ordered submicroscopic structure, as indicated by the birefringence associated with amyloid deposits, led Cohen and col- 91 leagues to undertake electron microscopic studies of human primary and secondary amyloid tissues as well as experimental amyloid (Cohen and Calkins, 1959) . Their first study clearly demonstrated that all forms of amyloid studied exhibit a comparable fibrillar ultrastructure in fixed tissue sections. In their initial study, Cohen and Calkins analyzed sections of amyloidotic tissues from rabbit with caseininduced amyloidosis (now known to be amyloid A (AA)); skin biopsy from a patient with clinically defined primary amyloidosis (now known to be AL amyloid); and kidney of a patient with amyloidosis of parenchymal organs, i.e., spleen liver and kidney (now known to be AA amyloid). It has been amply confirmed (reviewed by Cohen et al., 1982) that amyloid deposits of diverse origins in humans and animals exhibit a similar, fibrillar submicroscopic structure: bundles of straight, rigid fibrils ranging in width from 60 to 130 Å (average 75 to 100 Å) and in length from 1000 to 16,000 Å (Fig. 3) . The fibrillar morphology, upon analysis of negatively stained tissue sections by electron microscopy, was adopted as the second criterion by which amyloid is defined.
In their original paper, Cohen and Calkins suggested that human and animal amyloid possess a beaded structure. Gueft and Ghidoni (1963) suggested that amyloid fibrils are double, with an intrafibrillar space (25 Å) approximately equal to the diameter of each component (25 Å). Terry and colleagues (Terry et al., 1964) , studying human cerebral amyloid in the senile plaque of Alzheimer's disease, reported that the fibrils were 70 -90 Å in width and had a triple density, indicating a hollow center. Shirahama and Cohen (1967) carried out extensive high-resolution studies of the amyloid fibril in tissues, and from these and other studies reviewed by Cohen et al. (1982) , a consensus amyloid fibril structure was described, in which two ultrastructural features comprised the subunit structure of the amyloid fibril in vivo. A filamentous subunit structure, 25-35 Å in diameter, longitudinally constitutes the 75-to 100-Å-wide amyloid fibril. Two or more such subunit filaments, which cross each other occasionally, constitute the amyloid fibril in situ (Fig. 3) .
IN VITRO STUDIES OF AMYLOID FIBRIL PROTEINS
The identification of a fibril associated with the tinctorial properties of amyloid provided a basis upon which amyloid fibrils could be isolated from tissues. Initial isolation methods, based on a gentle physical separation, homogenization in saline, followed by low-speed centrifugation, yielded a layer of fibrils that was not present in sedimentation pellets of normal tissues (Cohen and Calkins, 1964) . When stained with Congo red, the fibril layer demonstrated green birefringence with polarizing optics. Shadow casting or negative staining defined the diameter of the isolated amyloid fibril as 75-100 Å. Filamentous subunits of 25-35 Å are arranged along the long axis of the fibril in a slow twist. Amyloid fibrils isolated from tissues and organs by physical separation, using sucrose gradient centrifugation (Shirahama and Cohen, 1967) , showed no remarkable differences in morphology from those tissues using the two criteria of Congophilia/green birefringence and fibrillar structure (Fig. 4) . The similarities in dimensions and morphology between isolated protein fibrils and amyloid fibrils in tissues has led to the widely held view that the proteinaceous fibrils studied in vitro over the past 20 years are biochemically and structurally identical to the amyloid fibrils observed in tissues.
However, this view has not taken into account the widespread immunohistochemical observation that other components of amyloid deposits in tissues do not form fibrils in vitro, but are invariably associated with all clinical/biochemical types of amyloid. These nonfibrillar components of amyloid include
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serum amyloid P component; heparan sulfate proteoglycans; and apolipoprotein E, which is associated with a number of types of amyloid, including the A␤ deposits of Alzheimer's disease.
Although the early isolation of amyloid fibrils from tissues employed differential centrifugation, after Pras introduced the water extraction method, (Pras et al., 1968) , the method has been almost universally used for extraction of almost all biochemical types of amyloid, except A␤ and APrP (Selkoe and Abraham, 1986; Prusiner and DeArmond, 1995) . With the low ionic strength Pras method, amyloid fibrils are separated from all proteins soluble in physiological saline by extraction of homogenates of amyloid-laden tissues with physiological saline followed by differential centrifugation. Then, amyloid fibrils are separated from other saline-insoluble tissue proteins by suspension in water. The isolated protein fibrils, insoluble in physiologic saline, exhibit Congophilia and green birefringence and are 80 to 100 Å in width.
The insoluble protein fibrils, extracted from tissues laden with amyloid fibrils, can be solubilized and size fractionated by gel filtration in denaturing agents, such as guanidine hydrochloride. This technological advance made possible the biochemical era of amyloid studies. Amino acid sequence determination of solubilized, denatured amyloid fibril proteins quickly led to the recognition that a biochemically unique protein was associated with each of the clinical syndromes (Tables I and II) . Since 1970, the number of biochemically distinct proteins, isolated from species throughout the animal kingdom, that satisfy the three criteria for amyloid is approaching 20 (Table II, Sipe, 1992) .
Studies from the Benditt and Glenner laboratories provided the first indication of the biochemical heterogeneity of amyloid. Glenner and co-workers (1971a) reported, on the basis of amino acid sequence analysis, that primary amyloidosis (now known as AL, but initially termed amyloid B by the Benditt laboratory (Benditt, 1976) ) is the result of the deposition of fragments of immunoglobulin light chains. Benditt and colleagues identified, on the basis of amino acid sequence analysis of fibrils isolated from tissues of patients with chronic and recurrent acute inflammatory diseases (secondary amyloidosis), a protein termed amyloid A (Benditt et al., 1971) . The existence of a third biochemical class of amyloid protein was revealed when Costa et al. (1978) and Skinner and Cohen (1981) reported that prealbumin, now known as transthyretin, is the fibril protein associated with familial amyloid polyneuropathy. Subsequent biochemical analyses, including amino acid sequencing, led to the identification of fragments (usually) of about 20 normally soluble proteins deposited in a specific anatomic pattern associated with specific clinical manifestation of disease (Table II) . In some cases, only a single organ of the body is affected, such as the pancreas in diabetes or the brain in Alzheimer's disease. In other cases, termed systemic amyloidoses, amyloid fibrils are deposited in multiple organs and tissues of the body and are thought to be derived from circulating plasma protein precursors (Sipe, 1992 (Sipe, , 1994 .
Today, amyloid is known to be a large biochemically and clinically heterogenous group of disorders of protein folding. Investigations of amyloid have led to the identification of previously unknown peptides and proteins implicated in a large number of important life processes. These proteins include the amyloid A protein and its precursor, the cytokine-regulated serum amyloid A (SAA); more than 70 transthyretin (TTR) variants; the cerebral amyloid ␤ protein, A␤, and its precursor protein A␤PP; the previously unrecognized diabetes-associated islet amyloid polypeptide (IAPP); and prion proteins that cause scrapie and other neurodegenerative diseases (APrP) (Cohen, 1967; Glenner, 1980; Sipe, 1992; Westermark et al., 1996; Benson and Uemechi, 1996; Prusiner and DeArmond, 1995) . X-ray diffraction analyses of isolated amyloid protein fibrils (Bonar et al., 1969; Glenner et al., 1974; Sunde and Blake, 1998) revealed that all proteinaceous amyloid fibrils were ordered in secondary structure, with the polypeptide backbone assuming the beta pleated sheet conformation and oriented perpendicular to the fibril axis. It is particularly noteworthy that, in the case of TTR, which is present in the vitreous fluid of FAP patients as well as throughout the body, the structure of the TTR fibril from the vitreous (for which the Pras extraction method would not have to be used) and the TTR fibril extracted from kidney (for which the Pras method or a modification of it would be used) are identical (Inouye et al., 1998) .
The association of the pentraxin SAP with tissue amyloid deposits was revealed by electron microscopic studies of fractions of tissue homogenates that had been separated on the basis of solubility and sedimentation under conditions of decreasing ionic strength (reviewed by Cohen et al., 1982) . It soon became apparent that, in addition to the fibrilrich fraction, another, pentagonal, particle, composed of five identical globular subunits, was invariably associated with amyloid deposits in tissues. The pentagonal component (P component) was identified immunochemically by Cathcart and co-workers (1965) as an alpha globulin. Bladen and co-workers (1966) , using a differential centrifugation technique, identified a small pentagonal structure about 90 Å in diameter (Fig. 4c) . Subsequent studies (reviewed by Pepys et al., 1997) led to the identification of a circulating blood protein nearly if not identical to the tissue protein. That blood protein is now called serum amyloid P component or SAP.
Despite the fact that SAP and heparan sulfate proteoglycans (HSPG) are always present in tissues with amyloid fibrils (Pepys et al., 1997; Snow and Wight, 1989; Magnus and Stenstad, 1997) , amyloid fibrils can be formed in vitro in their absence from several natural polypeptides, including insulin, glucagon, calcitonin, immunoglobulin light chains, and ␤ 2 -microglobulin (reviewed in Sipe, 1994) . Fibrils, similar in dimension and appearance to tissue-derived amyloid proteins, have also have been formed from synthetic peptides corresponding to part or all of AA, A␤, and IAPP. Amyloidogenic polypeptides can be influenced by heparin to assume the beta pleated sheet rather than the alpha helical conformation (McCubbin et al., 1988) . Studies of synthetic peptides led to the identification of amyloidogenic sequences in some precursors, such as AA, A␤, and IAPP, but not in others, such as AL and ATTR (reviewed in Sipe, 1994) . Some amyloidogenic precursors, such as TTR and immunoglobulin light chains, are predisposed to fibril formation by structural changes (amino acid substitutions) in disparate parts of the polypeptide, changes that promote unfolding. Others, such as A␤, AA, and AIAPP precursor, contain contiguous regions of amino acids that predispose to amyloid fibril formation. Recently, amyloid fibrils were generated by acid and heat denaturation of monellin, a sweet tasting plant protein (Konno et al., 1999) . De novo amyloid proteins have been generated from designed combinatorial libraries, in which all sequences were designed to share an identical pattern of alternating polar and nonpolar residues, and the side chains were varied combinatorially (West et al., 1999) . The resultant aggregates have fibrillar morphology, are Congophilic, and assume the beta pleated sheet secondary structure. The X-ray diffraction patterns of amyloid fibrils prepared in vitro and those extracted from tissues are similar (Glenner et al., 1974) . Apparently, the formation of proteinaceous amyloid fibrils is the result of a combination of factors, including the primary structure of the polypeptide and the thermodynamic parameters of the environment of the polypeptide (Kelly, 1998) .
Fibrils indistinguishable from those isolated from tissues were created by proteolytic digestion of Bence-Jones immunoglobulin light chain proteins (Glenner et al., 1971b; Linke et al., 1973; Shirahama et al., 1973) . The in vitro properties of fibrillar morphology, Congophilia, and green birefringence led to the conclusion that the AL fibrils were identical to those deposited in tissues in vivo. Thus, the in vitro observation of the properties of insolubility and resistance to proteolysis led to the assumption that amyloid fibrils exhibit the same properties in vivo and in vitro and that insolubility and resistance to proteolytic clearance lead to replacement and destruction of vital organs that are clinically affected with amyloidosis.
CURRENT MODEL OF AMYLOID FIBRILS IN TISSUES
As evidenced by other reports in this volume, we are currently entering a new molecular and thera-peutic era of amyloid, one in which prevention or reversal of amyloid fibril formation and the ensuing pathology in the body may be anticipated. Future multidisciplinary investigations of amyloid must be based upon a clear understanding of how the biophysical properties of proteins isolated from organs of patients afflicted with amyloidosis relate to the actual secondary structure of these fibrils in tissues.
Inoue and colleagues (Inoue et al., 1998a ) have compared experimental mouse AA amyloid fibrils in situ and after isolation by the Pras method (Pras et al., 1968) . On the basis of their observation on AA amyloid and on other forms, including A␤, ␤ 2 -microglobulin, and ATTR (Inoue et al., 1999 (Inoue et al., , 1998b (Inoue et al., , 1997 , they have proposed an alternative to the protein only, beta pleated sheet, protofilament amyloid fibril structure. Inoue, in collaboration with Kisilevsky and co-workers, has suggested that the 80-to 100-Å fibrillar structure in tissue is different from the structure of isolated protein in vitro. He proposes, on the basis of high-resolution electron microscopic studies, that in tissues, the amyloid fibril core is composed of helically wound 30-Å chondroitin sulfate proteoglycan (CSPG) double tracked structures enclosing a pentamer of amyloid P component (AP). Outside the CSPG are 45-to 50-Å heparan sulfate proteoglycans, to which AA protein filaments are attached. Presumably, the filaments are ordered to account for Congophilia and other specific histochemical staining, although the molecular basis for Congophilia is not clearly defined. Inoue and colleagues have proposed that the protein only fibril is formed artifactually as a result of the decreased ionic strength employed as part of the Pras extraction procedure. The Inoue model would consistently incorporate the reported HSPG binding sites in SAA (reviewed by Urieli-Shoval et al., 2000) and other amyloid proteins as well as the consistent changes in proteoglycan synthesis that precede amyloidogenesis (Kisilevsky and Fraser, 1997) .
The structure of the amyloid fibril in tissues has not been as rigorously analyzed as the protein only model of the amyloid fibril that has been derived from the past 3 decades of in vitro studies. In particular, a revisitation of the practice of isolation of amyloid fibrils from tissues, using the early "gentle amyloid fractionation techniques," is probably warranted. Future biochemical investigations will be more fruitful if heparan sulfate proteoglycan and AP content are analyzed, in addition to the major fibrilassociated protein. In particular, comparison of TTR fibrils from vitreous fluid and organs such as kidney from FAP patients, where the composition of extracellular matrix of these tissues and the fibril isolation procedures applied to them are distinct (Inouye et al., 1998) , may greatly enhance our understanding of the nature of amyloid fibril structure in vivo.
